Design Therapeutics Investor Relations Material
Latest events
Q4 2023
Design Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Design Therapeutics Inc
Access all reports
Design Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nucleotide repeat expansions. Their innovative approach centers on the development of GeneTAC™ gene targeted chimera small molecules. These molecules are designed to modulate the expression of disease-causing genes, offering potential treatments for a range of genetic disorders. The company's research portfolio includes projects targeting conditions such as Friedreich Ataxia, a severe progressive multi-system disease; Myotonic Dystrophy Type-1 (DM1), affecting muscle, heart, and other organs; and other nucleotide repeat expansion-driven diseases like Fragile X syndrome and Huntington disease. The company is headquartered in Carlsbad, California, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
DSGN
Country
🇺🇸 United States